Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The Hormone KL1: A Regulator of Breast Cancer Cell Metabolism.

Davidov B, Shmulevich R, Shabtay A, Rubinek T, Wolf I.

Isr Med Assoc J. 2019 Jul;21(7):504.

2.

Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma.

Peshes-Yeloz N, Ungar L, Wohl A, Jacoby E, Fisher T, Leitner M, Nass D, Rubinek T, Wolf I, Cohen ZR.

World Neurosurg. 2019 Oct;130:e324-e332. doi: 10.1016/j.wneu.2019.06.082. Epub 2019 Jun 20.

PMID:
31228703
3.

Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells.

Zinger L, Merenbakh-Lamin K, Klein A, Elazar A, Journo S, Boldes T, Pasmanik-Chor M, Spitzer A, Rubinek T, Wolf I.

Clin Cancer Res. 2019 May 1;25(9):2900-2914. doi: 10.1158/1078-0432.CCR-18-1505. Epub 2019 Feb 7.

PMID:
30733228
4.

Klotho suppresses colorectal cancer through modulation of the unfolded protein response.

Arbel Rubinstein T, Shahmoon S, Zigmond E, Etan T, Merenbakh-Lamin K, Pasmanik-Chor M, Har-Zahav G, Barshack I, Vainer GW, Skalka N, Rosin-Arbesfeld R, Varol C, Rubinek T, Wolf I.

Oncogene. 2019 Feb;38(6):794-807. doi: 10.1038/s41388-018-0489-4. Epub 2018 Sep 19.

PMID:
30232408
5.

New somatostatin-drug conjugates for effective targeting pancreatic cancer.

Ragozin E, Hesin A, Bazylevich A, Tuchinsky H, Bovina A, Shekhter Zahavi T, Oron-Herman M, Kostenich G, Firer MA, Rubinek T, Wolf I, Luboshits G, Sherman MY, Gellerman G.

Bioorg Med Chem. 2018 Jul 30;26(13):3825-3836. doi: 10.1016/j.bmc.2018.06.032. Epub 2018 Jun 30.

PMID:
30017114
6.

The Longevity Hormone Klotho is a New Player in the Interacion of the Growth Hormone/Insulin-Like Growth Factor 1 Axis.

Rubinek T, Wolf I, Modan-Moses D.

Pediatr Endocrinol Rev. 2016 Sep;14(1):9-18. doi: 10.17458/PER.2016.RWM.LongevityHormoneKlotho. Review.

PMID:
28508612
7.

Klotho response to treatment with growth hormone and the role of IGF-I as a mediator.

Rubinek T, Shahmoon S, Shabtay-Orbach A, Ben Ami M, Levy-Shraga Y, Mazor-Aronovitch K, Yeshayahu Y, Doolman R, Hemi R, Kanety H, Wolf I, Modan-Moses D.

Metabolism. 2016 Nov;65(11):1597-1604. doi: 10.1016/j.metabol.2016.08.004. Epub 2016 Aug 14.

PMID:
27733247
8.

The Role of Alpha-Klotho as a Universal Tumor Suppressor.

Rubinek T, Wolf I.

Vitam Horm. 2016;101:197-214. doi: 10.1016/bs.vh.2016.03.001. Epub 2016 Apr 6. Review.

PMID:
27125743
9.

Klotho and the Growth Hormone/Insulin-Like Growth Factor 1 Axis: Novel Insights into Complex Interactions.

Rubinek T, Modan-Moses D.

Vitam Horm. 2016;101:85-118. doi: 10.1016/bs.vh.2016.02.009. Epub 2016 Mar 16. Review.

PMID:
27125739
10.

Alteration in serum klotho levels in anorexia nervosa patients.

Wolf I, Stein D, Shahmoon S, Ziv SI, Hemi R, Kanety H, Rubinek T, Modan-Moses D.

Clin Nutr. 2016 Aug;35(4):958-62. doi: 10.1016/j.clnu.2015.07.013. Epub 2015 Jul 18.

PMID:
26243062
11.

Klotho expression in cervical cancer: differential expression in adenocarcinoma and squamous cell carcinoma.

Aviel-Ronen S, Rubinek T, Zadok O, Vituri A, Avivi C, Wolf I, Barshack I.

J Clin Pathol. 2016 Jan;69(1):53-7. doi: 10.1136/jclinpath-2015-202929. Epub 2015 Jul 24.

PMID:
26209729
12.

Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure-Function Analysis.

Ligumsky H, Rubinek T, Merenbakh-Lamin K, Yeheskel A, Sertchook R, Shahmoon S, Aviel-Ronen S, Wolf I.

Mol Cancer Res. 2015 Oct;13(10):1398-407. doi: 10.1158/1541-7786.MCR-15-0141. Epub 2015 Jun 25.

13.

The Effect of Klotho Treatment on Atherogenesis, Blood Pressure, and Metabolic Parameters in Experimental Rodent Models.

Kamari Y, Fingrut O, Shaish A, Almog T, Kandel-Kfir M, Harats D, Rubinek T, Wolf I.

Horm Metab Res. 2016 Mar;48(3):196-200. doi: 10.1055/s-0035-1549879. Epub 2015 May 7.

PMID:
25951321
14.

Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer.

Lojkin I, Rubinek T, Orsulic S, Schwarzmann O, Karlan BY, Bose S, Wolf I.

Cancer Lett. 2015 Jul 1;362(2):149-57. doi: 10.1016/j.canlet.2015.03.035. Epub 2015 Mar 28.

PMID:
25827069
15.

Association between decreased klotho blood levels and organic growth hormone deficiency in children with growth impairment.

Wolf I, Shahmoon S, Ben Ami M, Levy-Shraga Y, Mazor-Aronovitch K, Pinhas-Hamiel O, Yeshayahu Y, Hemi R, Kanety H, Rubinek T, Modan-Moses D.

PLoS One. 2014 Sep 8;9(9):e107174. doi: 10.1371/journal.pone.0107174. eCollection 2014.

16.

The aging suppressor klotho: a potential regulator of growth hormone secretion.

Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T.

Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E326-34. doi: 10.1152/ajpendo.00090.2014. Epub 2014 Jun 17.

17.

Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer.

Pud D, Har-Zahav G, Laitman Y, Rubinek T, Yeheskel A, Ben-Ami S, Kaufman B, Friedman E, Symon Z, Wolf I.

Breast Cancer Res Treat. 2014 Feb;144(1):123-31. doi: 10.1007/s10549-014-2832-y. Epub 2014 Jan 30.

PMID:
24477975
18.

Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.

Hasson SP, Rubinek T, Ryvo L, Wolf I.

Breast Care (Basel). 2013 Aug;8(4):248-55. doi: 10.1159/000354757. Review.

19.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA.

Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.

20.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

21.

Epigenetic silencing of the tumor suppressor klotho in human breast cancer.

Rubinek T, Shulman M, Israeli S, Bose S, Avraham A, Zundelevich A, Evron E, Gal-Yam EN, Kaufman B, Wolf I.

Breast Cancer Res Treat. 2012 Jun;133(2):649-57. doi: 10.1007/s10549-011-1824-4. Epub 2011 Oct 22.

PMID:
22042362
22.

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.

Breast Cancer Res Treat. 2012 Apr;132(2):449-61. doi: 10.1007/s10549-011-1585-0. Epub 2011 Jun 3.

PMID:
21638053
23.

KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer.

Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B, Wolf I.

Clin Cancer Res. 2011 Jul 1;17(13):4254-66. doi: 10.1158/1078-0432.CCR-10-2749. Epub 2011 May 13.

24.

Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.

Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.

Oncogene. 2010 Jan 7;29(1):26-33. doi: 10.1038/onc.2009.301. Epub 2009 Oct 5.

PMID:
19802015
25.

Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.

Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S.

J Biol Chem. 2009 Nov 27;284(48):33509-20. doi: 10.1074/jbc.M109.017608. Epub 2009 Sep 15.

26.

Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.

Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, Rubinek T.

Oncogene. 2008 Nov 27;27(56):7094-105. doi: 10.1038/onc.2008.292. Epub 2008 Sep 1.

PMID:
18762812
27.

Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.

Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S.

Cancer Res. 2007 Nov 1;67(21):10564-72.

28.

Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells.

Rubinek T, Chesnokova V, Wolf I, Wawrowsky K, Vlotides G, Melmed S.

Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92. Epub 2007 Jul 11.

29.

Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells.

Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S.

Mol Endocrinol. 2006 Dec;20(12):3321-35. Epub 2006 Sep 7.

PMID:
16959877
30.

15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.

Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP.

Cancer Res. 2006 Aug 1;66(15):7818-23.

31.

Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas.

Rubinek T, Rubinfeld H, Hadani M, Barkai G, Shimon I.

Endocrine. 2005 Nov;28(2):209-16.

PMID:
16388095
32.
33.

The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion.

Rubinek T, Yu R, Hadani M, Barkai G, Nass D, Melmed S, Shimon I.

J Clin Endocrinol Metab. 2003 Aug;88(8):3724-30.

PMID:
12915661
34.

Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.

Shimon I, Rubinek T, Bar-Hava I, Nass D, Hadani M, Amsterdam A, Harel G.

J Clin Endocrinol Metab. 2001 Aug;86(8):3635-40. Review.

PMID:
11502789
35.

Prolactin (PRL)-releasing peptide stimulates PRL secretion from human fetal pituitary cultures and growth hormone release from cultured pituitary adenomas.

Rubinek T, Hadani M, Barkai G, Melmed S, Shimon I.

J Clin Endocrinol Metab. 2001 Jun;86(6):2826-30.

PMID:
11397894
40.

The catalytic properties of the reverse transcriptase of the lentivirus equine infectious anemia virus.

Rubinek T, Loya S, Shaharabany M, Hughes SH, Clark PK, Hizi A.

Eur J Biochem. 1994 Feb 1;219(3):977-83.

41.
42.

Diversity in peritoneal macrophage response of CAPD patients to 1,25-dihydroxyvitamin D3.

Levy R, Klein J, Rubinek T, Alkan M, Shany S, Chaimovitz C.

Kidney Int. 1990 May;37(5):1310-5.

Supplemental Content

Loading ...
Support Center